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Bypassing molecular mechanisms of apoptosis deﬁciency may be of great utility for the successful treatment of
malignant tumors. We have discovered that imiquimod, a small-molecule immunomodulator, exerts rather tumor-
selective direct pro-apoptotic activity in vivo and in vitro towards cutaneous metastases of malignant melanoma, an
aggressive skin tumor. This pro-apoptotic activity was not detectable with resiquimod, a closely related structural
analogue whose pro-inﬂammatory activity is even greater than that of imiquimod. Unresponsiveness of some
melanoma metastases to imiquimod in vivo corresponded to resistance towards imiquimod-induced apoptosis
in vivo and in vitro. At the molecular level, the pro-apoptotic activity of imiquimod was independent of membrane-
bound death receptors, but depended on Bcl-2 expression as demonstrated by overexpression of Bcl-2 in
melanoma cells. Imiquimod is the ﬁrst topical compound with the potential to bypass molecular mechanisms of
apoptosis deﬁciency, a concept that may be relevant for other tumors as well.
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Successful treatment of metastatic melanoma represents
one of the most challenging, but often frustrating tasks in
today’s cancer management. This is largely due to the
tumor’s aggressive growth and its resistance to many
therapeutic regimens (Armstrong and Kricker, 1994; Chang
et al, 1998). Although various chemo- and/or immunothera-
pies, such as IFNa, interleukin-2, or tumor-directed vacci-
nation, have been evaluated in clinical trials and/or are in
current clinical use, all of these approaches, unfortunately,
met with rather limited success (Becker et al, 2000;
Schneeberger et al, 2000). Thus, novel approaches selec-
tively targeting melanoma cells are highly desirable. Among
the most appealing strategies are those that bypass
mechanisms developed by malignant tumors to resist
pro-apoptotic stimuli. Similar to other malignant tumors,
examples for such mechanisms described for melanoma
cells include mutations of the p53, Mcl-1 or Bcl-X(L) genes,
or alterations of NF-kB whose downregulation may sensi-
tize melanoma cells to TRAIL- and TNF-mediated apopto-
sis. In addition, elevated expression of various proteins
such as survivin and other IAPs may inhibit apoptotic
signals in melanoma cells (Hussein et al, 2003). Several
other mechanisms also have been implicated in apoptosis
deficiency of malignant melanoma, such as mutations in the
PITSRLE protein kinases resulting in diminished Fas- or
TNF-mediated apoptosis (Bayaert et al, 1997; Ariza et al,
1999; Nelson et al, 1999). Of particular note, many mecha-
nisms of apoptosis deficiency described for melanoma
involve resistance in death receptor-mediated pathways
(Griffith et al, 1998; Shin et al, 1999; Zhang et al, 2000;
Franco et al, 2001; Ugurel et al, 2002; Urquhart et al, 2002).
Given that apoptosis deficiency of malignant melanoma
appears to be associated with drug resistance in many
cases (Helmbach et al, 2003), it is conceivable that specifi-
cally bypassing mechanisms of apoptosis resistance will
result in an improvement of the as yet poor prognosis of
advanced malignant melanoma (Kaufmann and Earnshaw,
2000).
In clinical trials, imiquimod (1-(2-methylpropyl)-1H-imi-
dazo[4,5-c]quinolin-4-amine), a topical compound of Mr¼
240.3, has demonstrated high efficacy in the treatment of
basal cell carcinomas (Miller et al, 1994; Reiter et al, 1994;
Weeks and Gibson, 1994; Gibson et al, 1995; Wagner et al,
1997) or actinic keratoses (premalignant intraepidermal
keratinocyte neoplasias) (Miller et al, 1994; Megyeri et al,
1995). Interestingly, recent clinical observations also indi-
cate that imiquimod may be efficacious for topical treat-
ment of some melanoma metastases (Steinmann et al,
2000; Bong et al, 2002; Ugurel et al, 2002). It is thought that
imiquimod exerts its effect through elicitation of a strong
cell-mediated antitumoral immune response. Its action is
mediated, at least in part, through TLR-7-dependent
regulation of the transcription factor NF-kB, which upon
Abbreviations: IFN, interferon; IL, interleukin; mAb, monoclonal
antibody; MFI, mean fluorescence intensity; MM, malignant mela-
noma; TNF, tumor necrosis factor
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activation migrates to the nucleus and upregulates tran-
scription of various cytokines (Miller et al, 1994; Reiter et al,
1994; Tomai et al, 1995; Wagner et al, 1997; Hemmi
et al, 2002). In addition, imiquimod activates dendritic cells
(resident Langerhans cells in the skin) possibly resulting in
prolonged protective Th1-skewed immunity against viral
infections and malignant tumors (Miller et al, 1994; Tomai
et al, 1995). In addition, imiquimod has shown direct pro-
apoptotic activity towards epithelial cancer cells (Scho¨n
et al, 2003). Recently, resiquimod (4-amino-dimethyl-
2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), a
closely related compound of Mr¼ 314.4, has been demon-
strated to exert similar, in some experimental settings even
more pronounced, pro-inflammatory effects as its parent
analogue, imiquimod (Weeks and Gibson, 1994; Gibson
et al, 1995; Wagner et al, 1997; Wagner et al, 1999). There
are, however, no published clinical data thus far regarding
the efficacy of resiquimod in skin tumors. Overall, the
molecular basis of the antitumoral activity of imiquimod is
only poorly understood. Of note, it is generally thought that
neither imiquimod nor resiquimod exhibits direct antineo-
plastic activities.
Intrigued by recent clinical observations that imiquimod
is efficacious in the treatment of some cutaneous meta-
stases of malignant melanoma (Steinmann et al, 2000; Bong
et al, 2002; Ugurel et al, 2002) and that its antitumoral
activity extends beyond the known immunomodulatory
mechanisms (Scho¨n et al, 2003), we initiated investigations
to unravel molecular mechanisms underlying the mode of
action of imiquimod and resiquimod towards melanoma
cells. To our surprise, we found that imiquimod, but not
resiquimod, consistently induced apoptosis in melanoma
cells in vitro and in vivo in a rather tumor-selective manner.
Our data provide evidence for a direct antineoplastic activity
of imiquimod by directly inducing death receptor-indepen-
dent apoptosis in melanoma cells, which may synergisti-
cally enhance the profound immunomodulatory effects in
the treatment of malignant melanoma. This principle may be
relevant for other malignancies as well.
Results
Imiquimod, but not resiquimod, induces apoptosis
in melanoma cell lines In our initial experiments, four
different human melanoma cell lines as well as NHM
(established from five different donors) were cultured in
the presence of imiquimod or resiquimod at concentrations
of up to 50 mg per mL, which is within the range of
concentrations reached in vivo (i.e., 3-logs below the
marketed formulation, which is 50 mg per g). Unexpectedly
and not discernible from previously published data, marked-
ly diminished cell numbers were consistently observed in
the melanoma cell lines A375 and Mel-HO in a concentra-
tion-dependent manner (Fig 1a). The reduction of cell
numbers after incubation with 50 mg per mL imiquimod for
48 h reached 54% (  11.0) and 75% (  2.4), respectively,
as compared with vehicle-treated control cultures (po0.01
in both cases, Fig 1a, left panel). The reduction of cell
numbers after treatment with imiquimod was considerably
less pronounced in normal melanocytes and two other
melanoma cell lines, MeWO and Mel-2A (Fig 1a). No
reduction of cell numbers was observed when the cells
were cultured in the presence of resiquimod (Fig 1a, right
panel). Since direct antitumoral effects of imiquimod have
not been reported (Miller et al, 1994; Tomai et al, 1995), this
was a surprising observation and we sought to analyze the
underlying mechanisms.
In order to distinguish between necrosis and apoptosis,
we first assessed the direct cytotoxic effects of both
imiquimod and resiquimod on normal melanocytes and
four different melanoma cell lines (Mel-HO, Mel-2A, A375,
MeWo) using the LDH release method. Neither imiquimod
nor resiquimod exerted direct cytotoxic effects when
applied at concentrations ranging from 0 to 50 mg per mL
(Fig 1b). In contrast, when apoptosis was assessed by
ELISA measuring histone-bound DNA fragments, imiqui-
mod exerted dramatic pro-apoptotic effects in the two
sensitive melanoma cell lines (Mel-HO and A375) in a
concentration-dependent manner. After 24 h of incubation
with 50 mg per mL imiquimod, apoptosis was increased by
250%–900% as compared with vehicle-treated control
cultures (po0.01 in all cases, Fig 1c). In some experiments,
induction of apoptosis was even as high as 1400% as
compared with untreated controls. In contrast, when normal
melanocytes (i.e., cultures established from five different
donors) or the melanoma cell lines Mel-2A or MeWo were
studied, induction of apoptosis with imiquimod was
markedly weaker, if detectable at all, thus suggesting
relative resistance to imiquimod-induced apoptosis in these
cell populations (Fig 1c). Resiquimod did not induce
apoptosis in either of the cell lines studied (Fig 1c).
In order to confirm the pro-apoptotic effect of imiquimod
on the single-cell level by a second method, modified
TUNEL assays were performed using cultured A375 or Mel-
HO cells incubated with normal culture medium, 50 mg per
mL resiquimod, or 50 mg per mL imiquimod for 24 h (Fig 2a).
In control cultures and in resiquimod-treated cultures, the
percentage of apoptotic (TUNEL positive) cells was 0.7%
(  0.7) and 1.3% (  0.6), respectively. In contrast, when
the cultures were incubated with imiquimod, 15.8% (  3.0)
of the cells were apoptotic after 24 h (Fig 2a, right panel).
Thus, it appeared that the diminished in vitro cell numbers in
imiquimod-treated cultures of melanoma cells were due to
apoptosis induced by imiquimod. In contrast, resiquimod
again did not exert detectable pro-apoptotic effects in this
experimental system (Fig 2a, left panel).
In vivo induction of apoptosis by imiquimod in cuta-
neous metastases of malignant melanomas In order to
examine directly whether apoptosis was induced during
clinical use of imiquimod, thus being relevant in vivo, three
patients with multiple cutaneous melanoma metastases
were treated topically with imiquimod (Aldara 5% cream) as
described recently (Bong et al, 2002). From each patient,
several cutaneous melanoma metastases were biopsied
and processed for histopathological analysis prior to
initiating the treatment, and several additional metastases
were excised when signs of local inflammation were
clinically apparent. Overall, seven untreated metastases
and seven metastases treated topically with imiquimod
were analyzed. Utilizing a modified TUNEL assay, paraffin-
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embedded sections of these melanoma metastases were
subjected to BrdU-labeling of DNA fragments, and bound
BrdU was detected by immunohistochemistry. Whereas
few, if any, apoptotic cells were detected in untreated
metastases, the number of apoptotic, BrdU-positive cells
within the tumor tissue were greatly increased after
treatment with imiquimod (Fig 2b). Abundant apoptotic
cells were detected within the tumor nests, but not within
the inflammatory infiltrate surrounding the tumors (apoptotic
tumor cell visualized at high power magnification in Fig 2c).
Corresponding to the clinical response of some but not all
cutaneous metastases in clinical trials, however, and similar
to the divergent responses of different melanoma cell lines
in vitro, not all of the treated metastases were equally
sensitive to treatment with imiquimod: profound induction
of apoptosis was detected in five of seven metastases,
whereas two of seven metastases showed only a few
apoptotic cells following topical treatment with imiquimod.
This finding is consistent with the clinical observation that
some (the majority) of cutaneous metastases resolve under
topical imiquimod treatment, whereas others appear to be
resistant, although skin inflammation developed in either
case (Steinmann et al, 2000; Bong et al, 2002; Ugurel et al,
2002). Thus, it is conceivable that additional factors besides
induction of a cellular immune response, such as apoptosis
of tumor cells, are involved in the clinical outcome of
imiquimod-treated melanoma metastases.
Although our data suggest that susceptibility to apopto-
sis may be relevant for the clinical response of melanoma
metastases to topical imiquimod-treatment in patients, this
hypothesis is difficult to verify: the necessity to excise
metastases in order to assess the presence of apoptotic
cells prevents the follow-up needed to evaluate the clinical
response. In addition, only a minority of cutaneous
melanoma metastases do not resolve under topical imiqui-
mod treatment, and the response cannot be predicted from
clinical features alone. Hence, in order to overcome these
imminent problems at least in part, we established long-
term cultures from three metastases (obtained from two
patients), which proved imiquimod-resistant during clinical
use of imiquimod (Fig 3a). Of note, a prominent imiquimod-
induced cutaneous and peritumoral inflammatory reaction
was present in all cases, but apoptotic tumor cells were
conspicuously absent in vivo (i.e., in the excised, imiqui-
mod-treated metastases) as determined by TUNEL assays
performed on representative sections of the metastases
(Fig 3b). This observation provided circumstantial evidence
for an association of clinical unresponsiveness of some
Figure 1
Imiquimod, but not resiquimod, induces apoptosis in melanoma cell
lines. (a) Cultures of normal melanocytes (NHM, &), and the melanoma
cell lines A375 (’), Mel-HO (  ), and MeWo (m) were cultured with
imiquimod (left panel) or resiquimod (right panel) at the indicated
concentrations. Cell numbers in the cultures were determined after
48 h. Values shown represent average values of three independent
experiments (  SD). (b) Cultures of normal melanocytes (’ and  ) and
the melanoma cell lines Mel-HO (m and~), Mel-2A (& and  ) and A375
(4 and  ) were cultured with imiquimod (left panel) or resiquimod (right
panel) at the indicated concentrations. After 12 h or 48 h, direct
cytotoxicity (necrosis) was determined by LDH release (  SD) as
outlined in Materials and Methods. (c) Cultures of normal melanocytes
(&), and the melanoma cell lines A375 (’), Mel-HO (  ), MeWo (m), and
Mel-2A (~) were cultured in the presence of imiquimod (left panel) or
resiquimod (right panel) at concentrations ranging from 0 to 50 mg per mL
as indicated. After 24 h, apoptosis was assessed by determining histone-
bound DNA fragments as outlined in Materials and Methods. Values
shown represent average values of three independent experiments
(  SEM).
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melanoma metastases with the lack of apoptosis in vivo
under treatment with imiquimod. Next, long-term cultures
from these three imiquimod-resistant melanoma metas-
tases were established, and the identity of the cultured
melanoma cells was confirmed by melanin-production as
well as by flow cytometry assessing the expression of the
HMB-45 antigen (a marker for activated cells of melanocytic
origin) and Mel-CAM (CD146; Fig 3c). When these melano-
ma cell cultures were incubated in vitro with imiquimod, we
found that apoptosis was only slightly increased in vitro by
51%, 67% and 61%, respectively, after 24 h of incubation
with 50 mg per mL imiquimod as compared with vehicle-
treated control cultures (not statistically significant; Fig 3d).
In contrast, apoptosis was readily increased by 830% in
Mel-HO cells that were treated identically and served as a
positive control population in these experiments (po0.001
compared with untreated Mel-HO cells; Fig 3d).
Our results indicated that imiquimod is the first topical
compound that induces apoptosis in malignant melanoma
cells both in vitro and in vivo in a rather tumor-selective
manner. As there were some melanoma populations that
proved resistant to imiquimod-induced apoptosis, we
further assessed molecular mechanisms underlying this
intriguing pro-apoptotic activity of imiquimod. Given that
the structurally closely related compound, resiquimod, did
not exhibit melanoma-directed pro-apoptotic activity, we
utilized this compound as an ideal control substance in the
subsequent experiments.
Imiquimod-induced apoptosis is independent of mem-
brane-bound death receptors, but depends on caspase
activation Two major pathways have been described
through which cytostatic drugs may induce apoptosis.
The first involves activation of membrane-bound death
receptors, including the CD95 (Fas/APO-1), TNF, or TRAIL
receptor systems, and the other is dependent on mitochon-
drial cytochrome c release, both resulting in apoptotic cell
death (Thompson, 1995; Kaufmann and Earnshaw, 2000;
Dirsch et al, 2001). The latter pathway is largely dependent
on members of the Bcl-2 family of pro- and anti-apoptotic
proteins (Raisova et al, 2001). Thus, at least two mutually
not exclusive hypotheses can be delineated concerning the
molecular mechanisms involved in imiquimod-induced
apoptosis of melanoma cells: first, imiquimod could act
directly on membrane-bound death receptors, thus initiat-
ing the apoptotic signal transduction cascade. Second,
imiquimod could influence the Bcl-2-dependent mitochon-
drial pathway of apoptotic cell death.
In order to evaluate the first hypothesis, CD95 (Fas/APO-1)
expression by melanoma cell lines susceptible to imiquimod-
induced apoptosis was examined in cultures incubated with
imiquimod (50 mg per mL for 0–48 h). Alterations in expres-
sion were not detected by FACS or Western blot analysis
(data not shown). In order to assess whether imiquimod might
activate CD95 without altering its expression, we compared
apoptosis induced by imiquimod with apoptosis induced by
the CD95-activating CH-11 mAb. It was found that apoptosis
of Mel-HO melanoma cells was similarly increased four- to
seven-fold by imiquimod or the CH-11 mAb (po0.01 as
compared with vehicle controls in both cases; Fig 4a). But
when the cells were incubated with the CD95-directed
function-blocking ZB4 mAb, CH-11/CD95-mediated apop-
tosis was completely abrogated, whereas the pro-apoptotic
effect of imiquimod was not affected (po0.01 comparing
CH-11/ZB4-treated cells and imiquimod/ZB4-treated cells,
Fig 4a). Similar results were obtained with the melanoma
cell line A375 (data not shown). These findings were
Figure 2
Imiquimod induces apoptosis in melanoma cells in vitro and in
vivo. (a) Cultured Mel-HO melanoma cells were incubated with 50 mg
per mL resiquimod (left panel), or 50 mg per mL imiquimod (right panel).
Apoptosis was assessed after 24 h by TUNEL assay of the cultured
cells as outlined in Materials and Methods. TUNEL-positive (apoptotic)
cells are visualized by an intense blue staining. Scale bar¼10 mm. The
experiment shown is representative of three independent experiments
showing similar results. (b) Paraffin-embedded sections of biopsy
specimens of an untreated cutaneous melanoma metastasis (left
panels) and a metastasis from the same patient treated with imiquimod
for 14 d were subjected to a TUNEL assay as outlined in Materials and
Methods to visualize apoptotic cells. The upper panels depict the
epidermis overlying the metastases. Scale bar¼50 mm. Similar results
were obtained with five of seven metastases from three patients. (c)
High-power magnification of two melanoma cells in a metastasis
treated with imiquimod. Note the presence of melanin pigment clearly
identifying the cells as melanoma cells rather than infiltrating immune
cells.  indicates a non-apoptotic (TUNEL-negative) cell and 
indicates an apoptotic (TUNEL positive) cell. Scale bar¼ 20 mm.
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confirmed by TUNEL assays: although only 1.7% of Mel-HO
cells were TUNEL-positive in untreated control cultures, in
cultures incubated with imiquimod or a combination of
imiquimod and the ZB4 mAb, the proportion of TUNEL-
positive cells reached 17.3% and 13.7%, respectively (data
not shown). Thus, apoptosis induced by imiquimod ap-
peared to occur independent of CD95 (Fas/APO-1).
In the next series of experiments, the effects of
imiquimod on TRAIL (tumor-necrosis-factor-related apop-
tosis-inducing ligand) receptors, TRAIL-R1 to –R4 (DR4,
DR5, DcR1, and DcR2), were assessed. As demonstrated
by FACS analysis, TRAIL receptors 1 and 2 (DR4 and DR5)
were expressed by both Mel-HO and A375 melanoma cells
at moderate levels (MFI 30–60; data not shown). Expression
of TRAIL-R3 and TRAIL-R4 (DcR1 and DcR2) could not be
detected by means of FACS-analysis. Whereas the ligand,
TRAIL, binds to all four receptors, only TRAIL-R1 (DR4) and
TRAIL-R2 (DR5) confer intracellular proapoptotic signals via
activation of initiator caspases (e.g., caspase-8 (Cryns and
Yuan, 1999)). In contrast, TRAIL-R3 (DcR1) and TRAIL-R4
(DcR2) have been termed decoy receptors that do not
transmit pro-apoptotic signals and may even have anti-
apoptotic effects due to lacking or non-functional cytoplas-
mic death domains (Abe et al, 2000; Sheikh and Fornace,
2000). Similar to the effect observed with the stimulating
anti-CD95 mAb, CH-11, it was found that activation of
TRAIL receptors in Mel-HO cells and in A375 cells by the
natural ligand (TRAIL, 10 ng per mL for 24 h) resulted in a
marked and significant 3–6-fold induction of apoptosis
(po0.01 as compared with untreated control cultures;
Fig 4b). This pro-apoptotic activity of TRAIL was significant-
ly, albeit not completely diminished by either of the function-
blocking antibodies against TRAIL-R1 (DR4) and TRAIL-R2
(DR5) (reduction by 41% and 58%, respectively; po0.05 in
both cases as compared with TRAIL-treated cultures; Fig
4b). As expected, blocking of TRAIL-R3 (DcR1) or TRAIL-R4
Figure 3
Unresponsiveness of melanoma metastases to imiquimod-treatment in vivo corresponds to resistance against imiquimod-induced
apoptosis in vivo and in vitro. (a) Cutaneous melanoma metastases (left panel before treatment) were treated topically for 8 weeks with imiquimod
(Aldara 5% cream, right panel). Despite the development of a marked inflammatory response, there was local progression of this metastasis. (b)
Paraffin-embedded sections of a biopsy specimen of the cutaneous melanoma metastasis depicted in the right panel of (a) were subjected to a
TUNEL assay as outlined in Materials and Methods in order to visualize apoptotic cells (left panel). The right panel depicts a sequential section from
the same tissue specimen treated with TACS-nuclease in order to generate fragmentation of DNA in all cells (positive control). (c) A long-term culture
was established from the imiquimod-resistant melanoma metastasis as outlined in Materials and Methods, and the identity of the melanoma cells
was confirmed by FACS analysis demonstrating expression of HMB-45 (upper panel) and Mel-CAM (lower panel). The result shown is representative
for melanoma cell cultures established from three metastases. (d) Cell populations established from two different imiquimod-resistant melanoma
metastases (MM-1 and MM-2) and the melanoma line Mel-HO were cultured in normal medium (black bars) or in the presence of 50 mg per mL
imiquimod (open bars) for 24 h. Thereafter, DNA fragmentation was assessed as outlined in Materials and Methods. indicates po0.001 as
compared with control cells cultured in normal medium. n.s.¼not significant.
1270 SCHO¨N ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
(DcR2) did not inhibit the pro-apoptotic effect of TRAIL
stimulation (data not shown). In contrast, apoptosis induced
in Mel-HO and A375 cells by 25 or 50 mg per mL imiquimod
was not inhibited by TRAIL receptor-blocking antibodies
(Fig 4b), indicating that imiquimod-induced apoptosis was
independent of the TRAIL receptor system.
Finally, the effect of TNF-receptor inhibition on imiqui-
mod-induced apoptosis was assessed in Mel-HO and A375
cells. As demonstrated by FACS analysis, TNF-R2 was
almost absent on the surface of either cell line, whereas
TNF-R1 was expressed at low levels (MFI approximately
15–25, data not shown). Consistent with this finding,
incubation of the cells with TNFa resulted in only weak, if
any, induction of apoptosis (Fig 4c). In addition, function-
blocking antibodies to TNF-R1 or TNF-R2 did not signifi-
cantly affect the imiquimod-induced apoptosis (Fig 4c).
In order to assess whether imiquimod affected caspase-
mediated apoptotic pathways downstream of membrane-
bound death receptors, we have inhibited all known
caspases using the pan-caspase inhibitor zVAD-FMK. In
addition, we have blocked distinct caspase-mediated
pathways using specific fluoromethyl (FMK)-conjugated
oligopeptide inhibitors irreversibly blocking functional motifs
of the respective caspases. When the susceptible melano-
ma lines A375 or Mel-HO were incubated with the pan-
caspase inhibitor zVAD-FMK, imiquimod-induced apoptosis
was completely abrogated (Fig 4d). Likewise, blocking the
functions of caspases-3, -4, -6, -8, -9 or -10 also resulted in
significant inhibition of the imiquimod-induced apoptosis
in the two melanoma lines (po0.02 in all cases as com-
pared with imiquimod-treated controls). In contrast, inhibitors
of caspases-1, -2, and -13 did not significantly affect
imiquimod-induced apoptosis (Fig 4d). These results sug-
gested that, on the one hand, imiquimod-induced apoptosis
of melanoma cells involved activation of caspases mediating
death receptor-initiated and/or mitochondrial pathways.
Figure4
The pro-apoptotic effect of imiquimod in melanoma cells is independent of death
receptor functions, but involves caspase activation. (a) Subconfluent Mel-HO
melanoma cells were incubated for 24 h with normal culture medium (control), 50 mg
per mL imiquimod, 1 mg per mL of the Fas(CD95)-activating CH-11 mAb, 1 mg per mL
of the function-blocking Fas(CD95)-directed ZB4 mAb, or combinations of imiquimod
or the CH-11 mAb with the ZB4 mAb as indicated. Apoptosis of the cells (  SD) was
determined as outlined in Materials and Methods. The experiment shown is
representative of three independent experiments showing similar results.  indicates
po0.01 (as compared with cells treated with the respective stimulus alone). Similar
results were obtained with the melanoma line A375. (b) Subconfluent cultures of Mel-
HO melanoma cells were incubated for 24 h with normal culture medium, imiquimod
(50 mg per mL), TRAIL (TNF-related apoptosis-inducing ligand, 10 ng per mL), function-
blocking mAbs (50 ng per mL) against the TRAIL receptors DR4 or DR5, or
combinations of TRAIL or imiquimod with either of the TRAIL-blocking mAbs as
indicated. Apoptosis was assessed as in (a).  indicates po0.05 (as compared with the
TRAIL-treated control). The experiment shown is representative of two independent
experiments showing similar results. Similar results were obtained with the melanoma
line A375. (c) Mel-HO melanoma cells were incubated for 24 h with normal culture
medium, imiquimod (50 mg per mL), TNFa (1 ng per mL), function-blocking mAbs (3 mg
per mL) against the TNF receptors TNF-R1 or TNF-R2, or combinations of TNFa or imiquimod with either of the TNF-R-blocking mAbs as indicated
(  SD). The experiment shown is representative of three independent experiments showing similar results. Similar results were obtained with the
melanoma line A375. (d) Mel-HO melanoma cells were cultured for 24 h in normal medium (black bar), in the presence of 25 mg per mL imiquimod
(open bar), or combinations of imiquimod and specific oligopeptide inhibitors of caspases as indicated (crosshatched bars, zVAD inhibits all
caspases through binding of a shared functional motif). Apoptosis was assessed by determining histone-bound DNA fragents as outlined in
Materials and Methods.  indicates po0.02. The experiment shown is representative of two independent experiments using the Mel-HO cell line and
one experiment using the A375 cell line, all showing similar results.
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Direct inhibition of membrane-bound death receptors, on the
other hand, did not influence the imiquimod-induced
apoptosis in melanoma cells. Thus, it appeared that
imiquimod bypassed the signal transduction pathways
initiated by membrane-bound death receptors in melanoma
cell lines susceptible to imiquimod-induced apoptosis.
The pro-apoptotic effect of imiquimod is inversely
associated with Bcl-2 expression Since involvement of
membrane-bound death receptors in imiquimod-induced
apoptosis could not be detected, we next tested our
second hypothesis, involvement of Bcl-2 in the imiquimod-
induced apoptosis in melanoma cells. Given that the release
of cytochrome c and subsequent apoptotic cell death is
governed by the relative amounts and associations of anti-
apoptotic (Bcl-2, Bcl-xL) and pro-apoptotic (Bax, Bak, Bid,
etc.) proteins in the outer membrane of the mitochondria
(Raisova et al, 2001), we hypothesized that imiquimod
affected, at least in part, the mitochondrial Bcl-2-dependent
apoptotic pathway. In order to test this, we sought to assess
the expression of two counteracting proteins of the Bcl-2
family, Bcl-2 and Bax. The imiquimod-susceptible melano-
ma lines Mel-HO and A375 as well as the apoptosis-
resistant lines Mel-2A and MeWo were incubated with
normal medium, imiquimod, resiquimod, or the CD95-
stimulating antibody, CH-11. Mitochondrial lysates of these
melanoma cells were analyzed by Western blot, and
antibodies against both proteins, Bcl-2 and Bax, were used
subsequently on the same membrane. In the lysates of Mel-
HO and A375 cells treated with vehicle, the expression of
Bcl-2 was about 5–10-fold higher than the expression of
Bax. The same was true for cells treated with resiquimod. In
contrast, in lysates of cells treated with imiquimod the level
of the pro-apoptotic Bax was increased relative to the Bcl-2
expression level. A similar shift in Bcl-2 versus Bax
expression was seen in CH-11-treated Mel-HO and A375
cells (Fig 5a, top panel). In marked contrast to the
melanoma lines susceptible to imiquimod-induced apopto-
sis, vehicle-treated Mel-2A and MeWo cells revealed a
strong constitutive Bcl-2 signal but only a very weak
mitochondria-associated signal for Bax. Of note, treatment
with imiquimod, resiquimod, or the CD95-stimulating anti-
body CH-11 did not alter this relation between the highly
expressed Bcl-2 and the weakly expressed Bax (Fig 5a,
bottom panel). Thus, these results suggested a participation
of proteins of the Bcl-2 family in apoptosis induction by
imiquimod in the sensitive cell lines, and might be part of
an explanation as to why Mel-2A and MeWo cells were
resistant against induction of apoptosis by imiquimod.
In order to evaluate this important finding in more detail,
we sought to further analyze the influence of Bcl-2 on
induction of apoptosis by imiquimod. In proof-of-principle
experiments, Mel-HO cells (a cell line susceptible to
imiquimod-induced apoptosis) were transfected with a
murine bcl-2 construct (thus resembling the Bcl-2 situation
in the imiquimod-resistant lines) or the pIRES vector alone
(Mu¨ller-Wieprecht et al, 2000), and overexpression of Bcl-2
was confirmed by western blot analysis (data not shown).
This resulted in suppression of the imiquimod-induced shift
of mitochondrial Bax-expression (Fig 5b). In order to deter-
mine the relevance of Bcl-2 overexpression to imiquimod-
driven apoptosis, we again assessed DNA-fragmentation
Figure 5
Imiquimod induces apoptosis in melanoma cells in a Bcl-2-dependent manner. (a) Mel-HO cells (i.e., a melanoma cell line susceptible to
imiquimod-induced apoptosis, upper panel) and Mel-2A cells (i.e., a melanoma line resistant against imiquimod-induced apoptosis, bottom panel)
were incubated for 24 h in normal medium, the Fas-stimulating mAb CH-11, imiquimod, or resiquimod as indicated. Thereafter, mitochondria were
purified, and lyzed and Bcl-2 and Bax were assessed by western blot analysis as outlined in Materials and Methods. Imiquimod and the CH-11 mAb,
but not resiquimod, induce marked shifts of the Bcl-2/Bax ratio in Mel-HO cells, but not in Mel-2A cells. (b) Mel-HO/bcl-2 cells were treated identical
to the nontransfected cells depicted in (a), and mitochondrial Bax expression was assessed by western blot analysis. (c) Mock-transfected Mel-HO
cells (Mel-HO/pIRES, black bars) and Mel-HO cells overexpressing Bcl-2 (Mel-HO/bcl-2, crosshatched bars) were incubated with normal medium,
imiquimod, resiquimod, or the Fas-stimulating CH-11 mAb as indicated. After 24 h, apoptosis was assessed by determining histone-bound DNA
fragments. Values represent means of three independent cultures (  SD).  indicates po0.01.
1272 SCHO¨N ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
in the Bcl-2 overexpressing and the mock transfectants.
Mel-HO/pIRES and Mel-HO/bcl-2 transfectant cells were
incubated with normal medium, imiquimod, resiquimod, or
the CH-11 mAb for 24 h, and apoptosis was determined as
before. As expected, both imiquimod and the CH-11 mAb
induced marked apoptosis in the mock-transfected Mel-
HO/pIRES cells by 493% and 468%, respectively, whereas
resiquimod did not induce apoptosis (Fig 5c). In contrast,
both the baseline level of apoptosis as well as the imiquimod-
induced apoptosis were significantly reduced in untreated
cultures of Mel-HO cells overexpressing Bcl-2 as compared
with their mock-transfected counterparts (po0.02, Fig 5c).
Resiquimod did not exert any pro-apoptotic effects in either
of the cell lines (Fig 5c).
These findings suggested that imiquimod-induced apop-
tosis in melanoma cells is independent of membrane-bound
death receptors but is, at least to a considerable extent,
dependent on Bcl-2 expression.
Discussion
Preferential induction of apoptosis in tumor cells by a small-
molecule compound is an exciting anticarcinogenic con-
cept that may greatly benefit the management of some of
the most problematic tumors, such as malignant melanoma.
We demonstrate that imiquimod, a small-molecule topical
compound of the imidazoquinoline family of immune
response modifiers, was able to induce apoptosis in
malignant melanoma cells both in vitro and in vivo in a
rather tumor-selective manner. Given that imiquimod-
induced apoptosis in melanoma cells could not be
antagonized by functional blockade of various death
receptors, including Fas/APO-1 (CD95), TRAIL receptors,
and TNF receptors, this action was exerted downstream or
independent of death receptor activation. Thus, imiquimod-
mediated apoptosis appears to be relevant for effectively
bypassing mechanisms of malignant melanomas to resist
death receptor-mediated apoptotic stimuli (Griffith et al,
1998; Shin et al, 1999; Zhang et al, 2000; Franco et al, 2001;
Urquhart et al, 2002). Our results provide evidence for such
direct antineoplastic activity of imiquimod.
Whereas it is possible that in vivo cytokines, such as
TNFa or other pro-apoptotic soluble factors, pro-oncotic
factors such as reactive oxygen species, or cytotoxic T cells
participate in imiquimod-induced tumor destruction, it is
reasonable to expect that a direct pro-apoptotic activity
may contribute, given that the concentration of drug in the
marketed formulation is 3 logs greater than the concentra-
tion shown to cause apoptosis in vitro. In addition, the pro-
apoptotic effect occurred independent of T cell- or dendritic
cell-derived cytokines, as dendritic cells, the primary drug-
responsive cell type, and the principal source of released
cytokines (Reiter et al, 1994; Gibson et al, 1995; Burns et al,
2000; Suzuki et al, 2000; Hemmi et al, 2002), as well as
other leukocytes were not included in the cultures. The
finding that resiquimod did not lead directly to apoptosis
of melanoma cells does not necessarily predict how this
compound might act in a clinical setting, where cytokines
and leukocytes would be involved. But the formulation of
resiquimod currently under development is only 1.3 logs
higher in drug concentration than the highest doses tested
in vitro in our study (Spruance et al, 2001), and thus a direct
pro-apoptotic effect is unlikely to occur in vivo.
Of note, the clinical response of cutaneous melanoma
metastases to imiquimod treatment appeared to corres-
pond to the presence or absence of apoptosis both in vivo
and in vitro. This observation strongly suggests that
imiquimod-induced apoptosis is an important component
of the overall antitumoral activity of this compound. Given
that a profound inflammatory reaction was present in all
cases, i.e., metastases that resolved under treatment with
imiquimod as well as metastases that were resistant or even
progressed under such treatment, one may even specu-
late that susceptibility to imiquimod-induced apoptosis is
necessary for the desired net result, the eventual demise of
the tumor.
Two frequent mechanisms by which tumor cells achieve
chemoresistance have been described: the first involves
mutations in the p53 gene, and the second is associated
with alterations in pro- and/or anti-apoptotic proteins of the
Bcl-2 family. On the one hand, imiquimod was able to
induce apoptosis in both p53 wild-type and p53-mutated
melanoma lines (Mel-HO and A375) (Raisova et al, 2001;
Riebeling et al, 2002). It appears, therefore, that mutations
in the p53 gene do not primarily determine the sensitivity of
melanoma cells to imiquimod-induced apoptosis. This does
not formally rule out that p53 mutations may be involved in
some cases of resistance to imiquimod-induced apoptosis
in melanoma cells, since wild-type p53 has been shown to
upregulate Bax (Miyashita et al, 1994; Miyashita and Reed,
1995), thereby creating a functional link between Bax/Bcl-2
expression and the mutational status of p53. Loss of
functional p53 alone, however, cannot serve as a sufficient
explanation for susceptibility or resistance to imiquimod-
induced apoptosis in melanoma cells, at least under the
conditions used in our study.
On the other hand, the status of Bcl-2 appeared to be
involved in the susceptibility of melanoma cells to imiqui-
mod-induced apoptosis, since imiquimod-resistant mela-
noma lines exhibited markedly higher constitutive Bcl-2
expression than the susceptible lines, and imiquimod was
able to shift the mitochondria-associated Bcl-2/Bax ratio in
susceptible but not apoptosis-resistant melanoma lines.
The functional involvement of Bcl-2 in imiquimod-induced
apoptosis of melanoma cells was further confirmed when
Mel-HO transfectant cells overexpressing Bcl-2 were
analyzed: these cells were significantly less susceptible to
imiquimod-induced apoptosis as compared with their
mock-transfected counterparts. Blocking of caspases,
however, which are thought to mediate death receptor-
initiated apoptotic pathways, e.g., caspase-8, also resulted
in inhibition of imiquimod-induced apoptosis, thus suggest-
ing that imiquimod-induced apoptosis of melanoma cells is
not exclusively mediated by the mitochondrial pathway.
Although imiquimod exhibited profound pro-apoptotic
activity on several melanoma lines, its analogue, resiqui-
mod, showed very little, if any, such activity. The mechan-
isms underlying this striking difference between the
biological activities of these structurally closely related
compounds have not been clarified yet. But given that both
compounds exert similar effects on NF-kB-mediated and
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NF-kB-independent cytokine induction (Tomai et al, 1995;
Imbertson et al, 1998; Wagner et al, 1999), it is conceivable
that different structural motifs are required for the pro-
apoptotic and the pro-inflammatory activity, respectively.
Additional side chains on resiquimod, as compared with
imiquimod, may cause steric hindrance or binding to
molecular motifs not involved in apoptosis. In addition,
differential entry into living cells may contribute to the
distinct biological effects observed with the two com-
pounds (Scho¨n et al, 2003). Further molecular modifications
may unravel minimal structural requirements for either of
these functions. Based on our observations that imidazo-
quinolines of the resiquimod type exert profound pro-
inflammatory but no pro-apoptotic effects, although
compounds of the imiquimod type have both effects, it is
conceivable that in the future compounds of this family may
become available, which have preferential pro-apoptotic
effects while exerting only little inflammation. Such com-
pounds may overcome the profound systemic side-effects
observed when imiquimod was administered orally for
treatment of progressive cancers (Savage et al, 1996).
Overall, our results demonstrate that it is possible, in
principle, to use a topical small-molecule compound to
induce apoptosis directly and selectively in malignant
melanoma. By inducing apoptosis in the tumor cells, a
synergistic enhancement of the profound immunomodula-
tory effects of imiquimod may enable or at least speed the
clearance of melanoma metastases.
Materials and Methods
Cells, culture conditions, and Bcl-2 overexpression Four
established human melanoma cell lines were used in this study:
A375 (Giard et al, 1973), Mel-HO (Holzmann et al, 1988), Mel-2A
(Bruggen et al, 1981), and MeWo (Bean et al, 1975). Three
additional long-term melanoma cell populations (MM-1, MM-2,
and MM-3) were newly established from patients with metastatic
melanoma. Tissue specimens were obtained from metastases,
which proved clinically resistant to topical imiquimod. The meta-
stases were carefully freed from the surrounding connective
tissue, cut into small pieces (2–3 mm), and viable tumor cells were
obtained by gentle mechanical teasing of the tissue fragments.
Additional tumor cells were released from the tissue pieces by
subsequent Trypsin treatment (0.25% at 371C for 4 h). The identity
of the newly established melanoma cultures was confirmed by
FACS analysis demonstrating expression of the melanoma-
associated antigens HMB-45 and Mel-CAM (CD146) in all three
populations, and by melanin production in two of the new
populations (melanin was macroscopically visible in the culture
medium and microscopically within intracellular granules). All
melanoma cell lines were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS),
100 U per mL penicillin, and 100 mg per mL streptomycin (all from
Gibco/Life Technologies, Karlsruhe, Germany).
Cultures of normal human melanocytes (NHM) were established
from five donors and were grown in MCDB 153 medium supple-
mented with 5 mg per mL insulin, 10 mg per mL transferrin, 0.4%
bovine pituitary extract, 2 ng per mL bFGF, 1 nM cholera toxin, and
50 mM hydrocortisone (all from Biochrom, Berlin, Germany).
The generation of Mel-HO transfectant cells showing stable
overexpression of functional murine Bcl-2 using the pIRES/mbcl-2
expression construct was performed as described recently (Raisova
et al, 2001). Selection with 1 mg per mL geniticin (G418, Gibco/Life
Technologies) was performed, and stable expression of murine
Bcl-2 was routinely confirmed by western blot analysis.
Monoclonal antibodies Murine monoclonal antibodies (mAb)
specific for human CD95 (Fas/APO-1; clones CH-11 and ZB4,
Chemicon, Hofheim, Germany) were used in functional assays at
final concentrations of 1 mg per mL. For assays assessing the
function of TRAIL receptors 1–4, the following function-blocking
antibodies were used at final concentrations of 50 ng per mL:
anti-TRAIL-R1 affinity-purified goat IgG (#AF347, lot BWF 01),
anti-TRAIL-R2 affinity-purified goat IgG (#AF631, lot BVQ 02), anti-
TRAIL-R3 affinity-purified goat IgG (#AF630, lot BTO 02), and anti-
TRAIL-R4 affinity-purified goat IgG (#AF633, lot CFL 02, all from
R&D Systems, Wiesbaden, Germany). TNF-R1 was blocked by
mAb 225 (clone 16803, R&D Systems, 3 mg per mL), and TNF-R2
was inhibited by mAb 226 (clone 22221.311, R&D Systems, 3 mg
per mL). For western blot analysis, anti-murine Bcl-2 mAb (clone
100/D5, Novocastra, Dossenheim, Germany) was used at a 1:100
dilution, anti-human Bcl-2 mAb (clone 124, DAKO, Hamburg,
Germany) and anti-human Bax mAb (clone 2D2, Biozol, Eching,
Germany) was used at a 1:1000 dilution. Isotype-matched mouse
or goat immunoglobulins served as negative control.
Cytotoxicity assays Direct cytotoxicity was determined using a
lactate dehydrogenase-(LDH)-release detection kit according to
the manufacturer’s instructions (Roche Diagnostics, Mannheim,
Germany).
Flow cytometric analysis (FACS) Adherent cells were detached
from the tissue culture plastic ware using 0.25% trypsin/0.02%
EDTA in PBS. Cells were incubated at 41C for 45 min with 10 mg per
mL of the primary mAb, washed three times in PBS, and incubated
with PE-labeled goat anti-mouse IgG or FITC-labeled mouse anti-
goat IgG for 45 min at 41C. The cells were washed again three
times in PBS, fixed in 2% paraformaldehyde, and analyzed using
a fluorescence activated cell sorter (FACScan, Becton Dickinson,
Heidelberg, Germany) and the Cell Quest software (Becton
Dickinson).
Western blot analysis Cultured cells were solubilized in lysis
buffer (1% Triton-X-100, 50 mM Tris, pH 7.4, 150 mM NaCl
supplemented with Complete protease inhibitor (Boehringer
Mannheim, Mannheim, Germany). A Bradford assay was per-
formed to determine the protein concentrations in the lysates.
Equal amounts of protein were separated by SDS-PAGE and
transferred onto nitrocellulose membranes. Proteins of interest
were detected by specific mAbs followed by peroxidase-labeled
goat anti-mouse IgG or peroxidase-labeled goat anti-mouse IgM
and a chemiluminescence reaction (ECL from Amersham Phar-
macia, Buckinghamshire, GB). Signals were quantitated densito-
metrically (Fluor-S MultiImager, BioRad, Mu¨nchen, Germany).
Subcellular fractionation Cytosolic and mitochondrial extracts
were prepared as described recently (Raisova et al, 2001). Briefly,
after incubation with imiquimod or resiquimod, cells were detached
from the culture dishes, harvested in PBS, dissolved in hypotonic
buffer containing Complete protease inhibitor, and incubated on
ice for 15 min. Cells were then homogenized using a syringe (28
gauge), and centrifuged for 10 min at 41C and 10,000  g. The
cytosolic fractions were collected in the supernatants, and the
mitochondrial pellets were solubilized in lysis buffer (1% Triton-X-
100, 50 mM Tris, pH 7.4, 150 mM NaCl containing Complete
protease inhibitor). Western Blot analysis to detect Bcl-2 and Bax
within the mitochondrial fractions was performed as described
(Raisova et al, 2001).
Inhibition of caspase activation Cells that were induced by
imiquimod to undergo apoptosis were cultured in the presence or
absence of caspase inhibitors (caspase-specific oligopeptides
conjugated to fluoromethyl ketone), which bind to the active site of
the proteases, thereby irreversibly inhibiting the catalytic activity of
the enzymes. The following inhibitors have been used: Z-VAD-FMK
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(general caspase inhibitor), Z-WEHD-ZMK (caspase-1-inhibitor),
Z-VDVAD-ZMK (caspase-2-inhibitor), Z-DEVD-ZMK (caspase-
3-inhibitor), Z-YVAD-ZMK (caspase-4-inhibitor), Z-VEID-ZMK
(caspase-6-inhibitor), Z-IETD-ZMK (caspase-8-inhibitor), Z-LEHD-
ZMK (caspase-9-inhibitor), Z-AEVD-ZMK (caspase-10-inhibitor),
and Z-LEED-ZMK (caspase-13-inhibitor; all from R&D Systems,
Wiesbaden, Germany). Inhibitors were dissolved in DMSO at 10
mM and diluted with medium to a final concentration of 10 mM.
Cells were preincubated with inhibitors for 10 min prior to adding
the apoptotic stimulus (imiquimod at 25 mg per mL) for 24 h.
Control cultures received 1:1000 diluted vehicle (DMSO).
Induction of apoptosis in vitro Subconfluent cultures of cells
were incubated for 24 or 48 h with different pro-apoptotic stimuli.
In order to trigger CD95 (Fas)-mediated apoptosis, the cells were
incubated with the Fas-stimulating CH-11 mAb (1 mg per mL).
CD95 function was blocked using the ZB4 mAb. In order to
stimulate the TRAIL receptor system, 10 ng per mL of the natural
ligand (TRAIL, R&D systems) was added to the cultures. TRAIL
receptors 14 were blocked using 50 ng per mL of the respective
function-blocking antibodies. In other experiments, 1 ng per mL of
TNFa was added to the cultures, and TNF receptors were
blocked by 3 mg per mL of the respective function-blocking
mAbs. Imiquimod and resiquimod were dissolved in tissue
culture medium at 371C allowing concentrations up to 50 mg per
mL.
Apoptosis detection in vitro (DNA-fragmentation assay) For
detection of cytoplasmic histone-associated DNA-fragments,
the ‘‘Cell Death Detection ELISA’’ was used according to the
manufacturer’s instructions (Roche Diagnostics). The apoptosis
rates of treated cells were calculated as percent of controls. All
experiments were performed in duplicate or triplicate, and were
repeated at least three times.
Apoptosis detection in vitro (Terminal deoxynucleotidyltrans-
ferase-mediated d-UTP nick-end labeling; TUNEL assay) Cul-
tures of melanocytes or melanoma cells were incubated with
normal culture medium, 50 mg per mL imiquimod, or 50 mg per mL
resiquimod. After 24 h, the cells were detached from the cul-
ture flask using 0.25% trypsin, and fixed onto microscope slides
using 4% formalin. Thereafter, the cells were subject to apoptosis
detection by a modified TUNEL method (DermaTACS, R&D
Systems). Briefly, the cells were treated with proteinase K (1 mg
in 50 mL DNase-free water) in order to make the DNA fragments
accessible to the labeling enzymes, and endogenous peroxidase
was quenched using 3% H2O2 in methanol. DNA fragmentation in
individual apoptotic cells was then detected by labeling with
terminal deoxynucleotidyl transferase (TdT) and the thymidine
analogue bromodesoxy-uridine (BrdU). Incorporated BrdU was
detected by a highly specific and sensitive biotinylated anti-BrdU
antibody in combination with a streptavidin–peroxidase conjugate
(R&D Systems). Labeled cells were visualized with TACS Blue
Label (R&D Systems) generating an intense blue staining in cells
with DNA fragmentation. In each experiment, one aliquot of cells
was treated with TACS-nuclease (in order to generate fragmenta-
tion of DNA in all cells, positive control), and one aliquot from each
culture was used in which TdT had been omitted (negative control).
TUNEL-positive cells were quantitated microscopically (counting of
200 cells per assay condition).
Induction and detection of apoptosis in vivo Three patients
suffering from multiple cutaneous melanoma metastases were
treated topically with imiquimod (Aldara 5%) after obtaining written
informed consent to this treatment (Bong et al, 2002). Represen-
tative tumor nodules were removed surgically prior to initiating
this treatment, and additional metastases were biopsied after
a profound inflammatory response had developed in the treated
areas. Tissue specimens were fixed in 4% formalin in order to
prevent the loss of low-molecular-weight DNA fragments. Paraffin-
embedded sections from treated and untreated metastases,
respectively, were subjected to apoptosis detection by a modified
TUNEL method (DermaTACS) according to the manufacturer’s
instructions (R&D Systems). TUNEL-positive cells were visualized
with TACS Blue Label (R&D Systems) generating an intense blue
staining in cells with DNA fragmentation. In each experiment, one
section from each tissue was treated with TACS-nuclease (in order
to generate fragmentation of DNA in all cells, positive control), and
one section from each tissue was used in which TdT had been
omitted (negative control).
Statistical analyses All statistical analyses were performed using
the Excel software (Microsoft GmbH, Munich, Germany). Data are
displayed as mean  SD; p values were determined using the two-
tailed t test, and p valueso0.05 (confidence inter val of 95%) were
considered statistically significant. All statistical tests were two-
sided.
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